Chemotherapy Experienced Advanced Soft Tissue Sarcoma Therapeutics
1. Votrient patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(4 years ago) | |
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(4 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Dosage: TABLET
More Information on Dosage
VOTRIENT family patents
